December 16, 2024 12:07 PM EST

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Max Bayer

Pharma Reporter

A turbulent 2024 for Neurocrine is ending on a high note, after the biotech won FDA approval to treat congenital adrenal hyperplasia, a condition marked …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launch

Biohaven’s protein degrader cuts antibodies by 60%

Edgewise shares spike on Phase 2 success for muscular dystrophy drug

Neu­ro­crine gets FDA go-ahead to treat rare adren­al gland con­di­tion

Max Bayer

Pharma Reporter

Sign up to read this article for free.

more like this

Bris­tol My­ers drops cell ther­a­py pacts with Im­mat­ics, Cen­tu­ry as part of port­fo­lio re­view

Roche ter­mi­nates a Phase 3 Spark gene ther­a­py in he­mo­phil­ia A

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Check­point wins FDA ap­proval of check­point in­hibitor in ad­vanced skin can­cer, seeks part­ner for launch

Bio­haven’s pro­tein de­grad­er cuts an­ti­bod­ies by 60%

Edge­wise shares spike on Phase 2 suc­cess for mus­cu­lar dy­s­tro­phy drug

Neurocrine gets FDA go-ahead to treat rare adrenal gland condition

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Checkpoint wins FDA approval of checkpoint inhibitor in advanced skin cancer, seeks partner for launch

Biohaven’s protein degrader cuts antibodies by 60%

Edgewise shares spike on Phase 2 success for muscular dystrophy drug